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Abstract: Periocular xanthogranulomatous diseases are a rare group of disorders which 
are characterized by a predilection to affect the orbit and ocular adnexa and special histo-
pathological features, in particular infiltrates comprising non-Langerhans-derived foamy 
histiocytes and Touton giant cells. The differential diagnosis is difficult and occasionally 
definite diagnosis cannot be established even after clinical and histopathological find-
ings are taken together. We describe a case of a middle-aged man who presented with a 
10-year history of voluminous eyelid swelling with concomitant late-onset atopic mani-
festations, namely bronchial asthma and allergic rhinitis with nasal polyps. After thorough 
clinical and laboratory investigation, including a biopsy of the eyelid, we classified the 
patient’s disease to a rare entity that has been relatively recently described: periocular 
  xanthogranuloma associated with adult-onset asthma. In a review of the literature, no 
prospective trials concerning the treatment of this disease were found. The literature 
mainly contained case reports and case series in which corticosteroids and chemotherapy 
with alkylating agents have been reported to be beneficial. We treated our patient with 
a combination of oral corticosteroids and cyclophosphamide pulses and we observed 
substantial regression of the eyelid masses together with a normalization of systemic 
immunologic abnormalities.
Keywords: periocular xanthogranuloma, adult-onset asthma, non-Langerhans histiocytoses, 
cyclophosphamide, methylprednisolone
Introduction
Xanthogranulomatous diseases of the orbit are a group of rare disorders of unknown 
etiology and pathogenesis affecting the skin and subcutaneous tissues of the 
periorbital areas and the ocular adnexa. They are a form of non-Langerhans cell 
histiocytosis. The group displays considerable heterogeneity with some patients 
manifesting only local symptoms and signs at the face, and others manifesting 
systemic disorders, while its severity spans from an indolent disease to an inva-
sive disease that may even lead to death.1 Diagnosis is difficult and in some cases 
clinicopathological investigation fails to provide a classification more specific than 
non-Langerhans histiocyte proliferative disorder. Its treatment is largely empiri-
cal due to the rarity of the disease. Most published data concern small case series 
or case reports. Below we present a case of a man with long-standing periorbital 
xanthogranuloma who was treated with cyclophosphamide (CYC) and methylpred-
nisolone (MP). Informed consent and approval of the Local Institutional Ethical 
Committee was obtained.Clinical Ophthalmology 2010:4 106
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Case report
A 53-year-old Caucasian man presented to our outpatient 
rheumatology clinic for bilateral periorbital swelling. It 
had first started 10 years earlier with gradual swelling of 
both upper and lower eyelids and cheeks. The swelling was 
painless with a yellow–orange discoloration without other 
abnormalities of the overlying skin. It was so voluminous that 
it limited the opening of the eyes and distorted the patient’s 
physiognomy. Two years prior to the periorbital swelling he 
had developed bronchial asthma and allergic rhinitis with 
nasal polyps. Later, hypertension, benign prostate hyperplasia, 
and depression occurred. His family history also revealed 
hypertension and cardiovascular events. A few years before 
presenting to us, he had been investigated in a dermatologic 
hospital where he had an eyelid biopsy performed, consistent 
with xanthogranuloma. He was treated with immunoglobulin 
infusions, corticosteroids per os and isotretinoin without 
sustained improvement.
On physical examination, his vital signs were normal. 
There was obvious swelling of all four eyelids, the cheeks and 
temples which consisted of a painless, soft, slightly lobular 
tissue (Figure 1). The patient’s vision and ocular motility were 
not affected, although the opening of the eyes was limited. 
The rest of his physical examination was unremarkable.
Laboratory investigation showed eosinophilia (total 
eosinophils 1085/µL) and elevated acute phase reactants 
(erythrocyte sedimentation rate 53 mm/hour; C-reactive 
  protein 9 mg/L [normal  6 mg/L]). Urinalysis, liver and 
  kidney biochemistry, serum lipid profile and thyroid hormones 
were normal. Antithyroid autoantibodies were negative. 
Immunological tests showed elevated IgG immunoglobulin 
(2500 mg/dL, normal 751–1560 mg/dL), a slightly depressed 
IgA and normal IgE levels. Serum protein electrophoresis 
showed diffuse hypergammaglobulinemia without evidence of 
a monoclonal protein. Serum complement levels (C3 and C4) 
were low. Rheumatoid factor, antinuclear antibodies and anti-
neutrophil cytoplasmic antibodies were negative.
X-rays of the chest and the long bones were normal. A mag-
netic resonance imaging (MRI) of the orbits demonstrated eyelid 
swelling, mucosal thickening of all sinuses and abnormal signal 
and contrast uptake of the temporal, masseter and pterygoid 
muscles bilaterally corresponding to infiltration by a pathologi-
cal process. Moreover, the oculomotor muscles were swollen 
and infiltrated with pathological signal intensity (Figure 2). 
Computed tomography (CT) of the lungs showed small inter-
stitial nodules, bronchiolitis-like opacities and hilar lymph node 
enlargement (up to 2 cm). Abdominal CT was unremarkable. 
Pulmonary function tests showed mild expiratory flow limita-
tion. Pure protein derivative skin test was negative.
A new biopsy of the left upper eyelid showed large 
areas of xanthogranulomatous infiltration throughout the 
reticular dermis into the subcutaneous fat. The granulomatous 
Figure 1 Extensive eyelid swelling combined with less obvious swelling of the temples and cheeks.Clinical Ophthalmology 2010:4 107
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  infiltrate was composed of lymphocytes, epithelioid cells, 
foamy histiocytes and giant cells, many of them of Touton 
type. Foreign body giant cells were also present. The 
  lymphocytes were numerous and nodular lymphocytic 
aggregates were occasionally present (Figure 3). There was 
no evidence of necrobiosis, but foci of fibrosis could be 
observed. Immunohistochemistry showed that the histiocytes 
were CD68 positive and S-100 negative.
Clinical differential diagnosis included xanthelasma, 
thyroid disease, sarcoidosis, allergic granulomatosis,   
non-Langerhans histiocytoses (juvenile xanthogranuloma, 
papular xanthoma, xanthoma disseminatum), periocular 
  xanthogranuloma with adult-onset asthma (PXAOA), nec-
robiotic xanthogranuloma (NXG) and Erdheim–Chester 
disease (ECd). Immunological and histopathologic studies 
excluded the first four diagnoses. Considering that the patient 
suffered from an infiltrative nonmalignant non-Langerhans 
histiocytic disorder that was limited to facial structures and   
was associated with elevated acute phase reactants, 
a polyclonal activation of the humoral arm of the  adaptive 
Figure 2 Axial A) and coronal B) contrast-enhanced fat-suppressed T1-weighted MR images showing bilateral eyelid, lateral rectus oculomotor, masticatory and temporal 
muscle enlargement and enhancement.
Abbreviation: MR, magnetic resonance.
Figure 3 Diffuse infiltrate rich in lymphocytes, foamy histiocytes, and giant cells (hematoxylin and eosin: x250). A) Giant cells of Touton type, B) nodular lymphoid infiltrate.Clinical Ophthalmology 2010:4 108
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immunity, and atopic manifestations, we favored the 
  diagnosis of PXAOA.
The patient was treated with 6 monthly infusions of 
CYC 750 mg/m2 body surface area and MP 0.8 mg/kg body 
weight per os with gradual tapering. After completion of all 
six CYC infusions the periorbital swelling had significantly 
regressed (Figures 4A, B), complement levels had normal-
ized and a repeat MRI of the orbits showed regression of the 
swelling and of the abnormal signal of the eyelids and the 
masticatory and oculomotor muscles (Figures 4C, D). MP 
was further tapered, while azathioprine was added to maintain 
the effect of the CYC/MP combination and allow for further 
  corticosteroid tapering.
Discussion
Nonmalignant non-Langerhans histiocytoses are classified 
on the basis of the cell types that predominate in the histo-
pathologic specimens and on whether the lesions are solitary, 
multiple or systemic.2 Diseases with predominant xanthoma-
tized histiocytes, such as juvenile xanthogranuloma, papular 
xanthoma, xanthoma disseminatum, etc, form a major part 
of this group. Pathologically, they typically demonstrate 
an abundance of foamy histiocytes and Touton giant cells. 
The age of disease onset, the specific skin changes and the 
potential involvement of other organs and tissues, including 
the orbit and ocular adnexa, varies according to the particular 
disease subtype.3,4
NXG displays histopathologic features similar to xantho-
granulomas, ie, foamy cells and Touton giant cells in relation 
with areas of collagen degeneration, lymphoid aggregates or 
follicles occasionally with germinal centers, plasma cell foci 
and cholesterol clefts.5 It affects equally men and women 
in their sixth decade and usually involves the periorbital 
areas, trunk, and proximal parts of the extremities. Lesions 
initially resemble xanthelasmas, but they gradually progress 
to indurate yellow-brownish plaques with a tendency to 
ulcerate and even cause destructive skin changes. Ocular 
manifestations include conjunctivitis, scleritis, corneal per-
foration, uveitis and orbital mass. It is often associated with 
immune dysfunction, namely monoclonal paraproteinemia 
(80%), hypocomplementemia and cryoglobulinemia, whereas 
it occasionally is associated with multiple myeloma, non-
Hodgkin lymphoma (NHL) or other hematologic dyscrasias.6 
Association with bronchial asthma is weak, if any.4 The cause 
Figure 4 Six months of treatment. Significant regression of eyelid swelling (A, B). Follow-up MRI: axial (C) and coronal (D) contrast-enhanced fat-suppressed T1-weighted MR 
images shows normalization of eyelid, lateral rectus oculomotor, masticatory and temporal muscle.
Abbreviation: MRI, magnetic resonance imaging.Clinical Ophthalmology 2010:4 109
Periocular xanthogranuloma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of the disease remains elusive, although it is presumed that 
special functional properties of the paraprotein are respon-
sible for an aberrant immune response.6
ECd is characterized by abnormal and aggressive pro-
liferation of non-Langerhans foamy histiocytes. The main 
manifestations are osteosclerosis of the diaphyses and 
metaphyses of the long bones and diabetes insipidus due 
to pituitary involvement. Ocular manifestations include 
xanthelasma-like lesions and exophthalmos and respiratory 
involvement includes pulmonary infiltrates, fibrosis and 
pleural effusion.4,7
Recently, Jakobiec and colleagues4 described six patients 
with periocular xanthogranuloma and concomitant asthma. 
They termed the condition periocular xanthogranuloma 
with adult-onset asthma. One of the patients, on whom a 
necrobiotic lesion was observed later in the disease course, 
developed paraproteinemia as well. Hence, the researchers 
suggested there might be an overlap between NXG and 
PXAOA. Whether they form different aspects of the same 
disease spectrum or are different diseases is not clearly evi-
dent. On clinical grounds, relating PXAOA and NXG might 
have therapeutic and prognostic implications, particularly 
regarding the risk for hematologic dyscrasias.
Sivak-Callcott and colleagues1 reviewed 137 cases of 
adult xanthogranulomatous disease of the orbit and ocular 
adnexa, among them 21 cases of PXAOA, 72 cases of NXG 
and 36 cases of ECd. Patients with PXAOA often had signs of 
immune dysfunction, such as polyclonal gammapathy and reac-
tive lymphadenopathy, while one patient developed Burkitt’s 
lymphoma and another NHL. Histopathologically NXG more 
often showed pallisading epithelioid histiocytes together with 
necrobiosis, while large lymphocytic aggregates were more 
common in PXAOA. Fibrosis was more evident in ECd.
Our patient had periorbital disease with concurrent 
immunological abnormalities, namely mediastinal lymph-
adenopathy, hypocomplementemia, and diffuse hypergam-
maglobulinemia. Furthermore, atopic phenomena (asthma, 
rhinosinusitis, eosinophilia) were present. These had 
appeared close to the onset of the eyelid swelling. ECd diag-
nosis was rejected because there was no bone involvement, 
while lung manifestations in ECd do not include asthma.4 
Juvenile xanthogranuloma can be differentiated on clinical 
grounds (lesions are usually solitary, but, when multifocal, 
other parts besides the eyelids are commonly affected).3 
Xanthoma disseminatum can be excluded, since the patient 
exhibited no axillary or inguinal lesions and no mucosal 
involvement.3 Papular xanthoma histologically rarely exhibits 
inflammatory infiltrates.3
Regarding NXG, whereas no sites of necrobiosis were 
evident in two histopathological examinations, the presence 
of such lesions elsewhere in the pathological tissue cannot 
be excluded. Furthermore, foci of fibrosis were observed 
that might represent scarring of a previously necrobiotic 
focus. However, ulceration or ocular inflammation had never 
occurred in 10 years and no monoclonal B-cell abnormality 
could be observed. For those reasons we classified the patient 
as suffering from PXAOA.
The management of the condition remains empirical, due 
to its rarity. Surgical excision is often followed by disease 
recurrence and scarring.4,6 Orbital radiotherapy and topi-
cal corticosteroids have been used with variable results in 
some cases of NXG.5,6,8 Patients with PXAOA often admit 
improvement of periorbital swelling, whenever treated with 
systemic corticosteroids for their asthma.4,9 There have also 
been various reports of PXAOA responding to systemic 
corticosteroids, but the disease often recurs after cortico-
steroid withdrawal, as was the case for our own patient as 
well.10 There are also several reports of effective treatment of 
NXG with chemotherapeutic agents particularly alkylating 
agents, such as chrorambucil, melphalan and CYC alone or 
in combination with corticosteroids.5,6,8,11,12 Jakobiec suggests 
that patients without systemic disease receive a course of 
high-dose systemic steroids and periorbital radiotherapy; if 
the disease does not respond, then light chemotherapy with 
corticosteroids could be administered.4
Long-term outcomes of PXAOA following various thera-
peutic modalities are rarely reported. Two of three patients 
reported by Jakobiec relapsed after surgery and corticosteroids 
were only temporarily effective in one of them. One patient 
with concomitant monoclonal gammapathy responded to 
combined chemotherapy.4 In the series by Sivak-Callcott, 
surgery was successful in six out of eight and corticosteroids 
in two out of two cases of PXAOA.1 A 46-year-old patient 
worsened after topical radiotherapy and later, following 
treatment with a combination of corticosteroids and cyclo-
sporine A, he developed a lymphoma. The disease ultimately 
responded to bone marrow suppressive treatment and long-
term low dose prednisone. Another patient, though, responded 
to the corticosteroids-cyclosporine A combination. Overall, 
no deaths due to PXAOA were reported.1
In rheumatology considerable experience exists concern-
ing the use of CYC in inflammatory diseases owing to B-cell 
dysregulation, such as lupus nephritis, or granulomatous 
autoimmune diseases, such as Wegener’s granulomatosis 
and Churg–Strauss syndrome. We thus treated the patient 
with 6 monthly CYC infusions and MP aiming at a rapid Clinical Ophthalmology 2010:4
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  suppression of the inflammatory process and a disease 
regression that would sustain after corticosteroid with-
drawal.
As regards prognosis, the potential overlap between 
PXAOA and NXG and the known association of NXG with 
hematologic malignancies require close follow-up of the 
patient in order to timely uncover a potential emerging malig-
nancy. Thus, regular clinical evaluation, full blood count, 
inflammatory markers, and serum protein electrophoresis 
should be performed.
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